NIH To Study HIV Vaccine In HIV-Negative Men, Transgender People

The National Institutes of Health (NIH) will conduct a phase III HIV vaccine efficacy trial at multiple clinical research sites in North America, South America and Europe, the agency announced Monday (July 15). The study comes as the Trump administration and HHS aim to end the HIV epidemic by 2030, and as FDA implements policies to advance the development of drugs to prevent or treat HIV. Janssen Vaccines & Prevention, part of the Janssen Pharmaceutical Companies of Johnson & Johnson,...